Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer
{{output}}
Background: Bemarituzumab, a monoclonal antibody targeting fibroblast growth factor receptor 2b (FGFR2b), is under evaluation in phase 3 trials of gastric cancer (GC) trials. However, data on the characteristics, prognostic signi... ...
